Literature DB >> 18081691

Translational mini-review series on complement factor H: structural and functional correlations for factor H.

C Q Schmidt1, A P Herbert, H G Hocking, D Uhrín, P N Barlow.   

Abstract

The 155-kDa glycoprotein, complement factor H (CFH), is a regulator of complement activation that is abundant in human plasma. Three-dimensional structures of over half the 20 complement control protein (CCP) modules in CFH have been solved in the context of single-, double- and triple-module segments. Proven binding sites for C3b occupy the N and C termini of this elongated molecule and may be brought together by a bend in CFH mediated by its central CCP modules. The C-terminal CCP 20 is key to the ability of the molecule to adhere to polyanionic markers on self-surfaces where CFH acts to regulate amplification of the alternative pathway of complement. The surface patch on CCP 20 that binds to model glycosaminoglycans has been mapped using nuclear magnetic resonance (NMR), as has a second glycosaminoglycan-binding patch on CCP 7. These patches include many of the residue positions at which sequence variations have been linked to three complement-mediated disorders: dense deposit disease, age-related macular degeneration and atypical haemolytic uraemic syndrome. In one plausible model, CCP 20 anchors CFH to self-surfaces via a C3b/polyanion composite binding site, CCP 7 acts as a 'proof-reader' to help discriminate self- from non-self patterns of sulphation, and CCPs 1-4 disrupt C3/C5 convertase formation and stability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18081691      PMCID: PMC2276926          DOI: 10.1111/j.1365-2249.2007.03553.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  73 in total

1.  Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).

Authors:  M A Abrera-Abeleda; C Nishimura; J L H Smith; S Sethi; J L McRae; B F Murphy; G Silvestri; C Skerka; M Józsi; P F Zipfel; G S Hageman; R J H Smith
Journal:  J Med Genet       Date:  2005-11-18       Impact factor: 6.318

Review 2.  Atypical haemolytic uraemic syndrome.

Authors:  David Kavanagh; Timothy H J Goodship; Anna Richards
Journal:  Br Med Bull       Date:  2006-09-11       Impact factor: 4.291

3.  Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome.

Authors:  Pilar Sánchez-Corral; David Pérez-Caballero; Olatz Huarte; Ari M Simckes; Elena Goicoechea; Margarita López-Trascasa; Santiago Rodríguez de Córdoba
Journal:  Am J Hum Genet       Date:  2002-11-06       Impact factor: 11.025

4.  Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein.

Authors:  Matti Laine; Hanna Jarva; Sanna Seitsonen; Karita Haapasalo; Markus J Lehtinen; Nina Lindeman; Don H Anderson; Patrick T Johnson; Irma Järvelä; T Sakari Jokiranta; Gregory S Hageman; Ilkka Immonen; Seppo Meri
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

5.  Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).

Authors:  C Licht; S Heinen; M Józsi; I Löschmann; R E Saunders; S J Perkins; R Waldherr; C Skerka; M Kirschfink; B Hoppe; P F Zipfel
Journal:  Kidney Int       Date:  2006-04-12       Impact factor: 10.612

6.  Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid.

Authors:  P T Johnson; K E Betts; M J Radeke; G S Hageman; D H Anderson; L V Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-01       Impact factor: 11.205

7.  Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces.

Authors:  Viviana P Ferreira; Andrew P Herbert; Henry G Hocking; Paul N Barlow; Michael K Pangburn
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

8.  The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells.

Authors:  Andreas P Sjöberg; Leendert A Trouw; Simon J Clark; Jonatan Sjölander; Dick Heinegård; Robert B Sim; Anthony J Day; Anna M Blom
Journal:  J Biol Chem       Date:  2007-02-09       Impact factor: 5.157

9.  His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form.

Authors:  Simon J Clark; Victoria A Higman; Barbara Mulloy; Stephen J Perkins; Susan M Lea; Robert B Sim; Anthony J Day
Journal:  J Biol Chem       Date:  2006-06-20       Impact factor: 5.157

10.  Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.

Authors:  Matthew C Pickering; Elena Goicoechea de Jorge; Rubén Martinez-Barricarte; Sergio Recalde; Alfredo Garcia-Layana; Kirsten L Rose; Jill Moss; Mark J Walport; H Terence Cook; Santiago Rodriguez de Córdoba; Marina Botto
Journal:  J Exp Med       Date:  2007-05-21       Impact factor: 14.307

View more
  62 in total

Review 1.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

2.  Outsmarting the host: bacteria modulating the immune response.

Authors:  Matthew D Woolard; Jeffrey A Frelinger
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Richard Hauhart; Celia J Fang; Paula Bertram; John P Atkinson
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

4.  Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.

Authors:  Serena Bettoni; Elena Bresin; Giuseppe Remuzzi; Marina Noris; Roberta Donadelli
Journal:  J Biol Chem       Date:  2016-02-22       Impact factor: 5.157

5.  Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

Authors:  Markus J Harder; Nadine Kuhn; Hubert Schrezenmeier; Britta Höchsmann; Inge von Zabern; Christof Weinstock; Thomas Simmet; Daniel Ricklin; John D Lambris; Arne Skerra; Markus Anliker; Christoph Q Schmidt
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

6.  Structure of factor H-binding protein B (FhbB) of the periopathogen, Treponema denticola: insights into progression of periodontal disease.

Authors:  Daniel P Miller; Jessica K Bell; John V McDowell; Daniel H Conrad; John W Burgner; Annie Héroux; Richard T Marconi
Journal:  J Biol Chem       Date:  2012-02-24       Impact factor: 5.157

7.  Mechanisms of Host-Pathogen Protein Complex Formation and Bacterial Immune Evasion of Streptococcus suis Protein Fhb.

Authors:  Xueqin Li; Peng Liu; Shuzhen Gan; Chunmao Zhang; Yuling Zheng; Yongqiang Jiang; Yuan Yuan
Journal:  J Biol Chem       Date:  2016-06-24       Impact factor: 5.157

8.  Smallpox inhibitor of complement enzymes (SPICE): regulation of complement activation on cells and mechanism of its cellular attachment.

Authors:  M Kathryn Liszewski; Paula Bertram; Marilyn K Leung; Richard Hauhart; Lijuan Zhang; John P Atkinson
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

9.  The central portion of factor H (modules 10-15) is compact and contains a structurally deviant CCP module.

Authors:  Christoph Q Schmidt; Andrew P Herbert; Haydyn D T Mertens; Mara Guariento; Dinesh C Soares; Dusan Uhrin; Arthur J Rowe; Dmitri I Svergun; Paul N Barlow
Journal:  J Mol Biol       Date:  2009-10-14       Impact factor: 5.469

10.  Structure of complement fragment C3b-factor H and implications for host protection by complement regulators.

Authors:  Jin Wu; You-Qiang Wu; Daniel Ricklin; Bert J C Janssen; John D Lambris; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.